The appropriate use of agents that inhibit vascular endothelial growth factor (VEGF) can bring significant improvements to both short-term and long-term visual acuity for patients with neovascular AMD.
The limiting factor for clinical improvement may be as simple as too few injections.
“You can do a very good job of administering anti-VEGF therapy tailored to the individual patient’s needs while limiting expenses and exposure to risks by avoiding unnecessary injections,” said Michael Larsen, MD, DMSc, professor of clinical ophthalmology at the Rigshospitalet and the University of Copenhagen, Denmark.
“It is a demanding task though, because if you give an average of four injections per year, it will be too little to provide patients something that approaches the quality of results that has been demonstrated in controlled clinical trials,” he said. “You have to give closer to seven or eight injections and you have to time it right.”
Dr. Larsen explored real world results of anti-VEGF treatment for wet AMD and found that most patients require seven to eight anti-VEGF injections annually and about 10 office visits to assess clinical status.